Brief: Arcutis Presents Late-Breaking Data From Integument-Ped Phase 3 Trial Of Roflumilast Cream

Arcutis Biotherapeutics

10/03/2024 20:04

March 10 (Reuters) - Arcutis Biotherapeutics Inc
 ARQT.O :
    * ARCUTIS PRESENTS LATE-BREAKING DATA FROM INTEGUMENT-PED
PHASE 3
TRIAL OF ROFLUMILAST CREAM 0.05% IN ATOPIC DERMATITIS IN
CHILDREN AGES 2 TO 5
    * INVESTIGATIONAL ROFLUMILAST CREAM 0.05% MET PRIMARY
ENDPOINT AND
ALL SECONDARY ENDPOINTS
    * RESULTS FOR ROFLUMILAST CREAM SHOW CONSISTENT EFFICACY AND
FAVORABLE SAFETY,TOLERABILITY PROFILE FROM INTEGUMENT-1,
INTEGUMENT-2 PIVOTAL TRIALS

Source text for Eikon:  ID:nGNX4PLqR5 
Further company coverage:  ARQT.O 

 ((Reuters.Briefs@thomsonreuters.com;))